Skip to main content
Top
Gepubliceerd in:

05-04-2024

Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV)

Auteurs: Mourad Abbas, Carrieri Patrizia, Marcellin Fabienne, Bourliere Marc, Parlati Lucia, Carrat Fabrice, Duracinsky Martin, Protopopescu Camelia

Gepubliceerd in: Quality of Life Research | Uitgave 6/2024

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Patient Reported Outcomes Quality of Life survey for HCV (PROQOL-HCV) is a specific tool developed to assess health-related quality of life (HRQoL) in patients with chronic hepatitis C receiving direct-acting antivirals (DAA). Thresholds for clinically meaningful changes in PROQOL-HCV scores should be documented to improve the tool’s use in clinical practice. This study aimed to estimate the minimal clinically important differences (MCIDs) in PROQOL-HCV scores before and after HCV cure by DAA among participants in the prospective cohort ANRS-CO22 HEPATHER.

Methods

Data from 460 chronic HCV patients were collected at DAA initiation (baseline) and 24 weeks after treatment end. MCIDs were estimated for the six HRQoL dimensions (Physical Health (PH), Emotional Health (EH), Future Uncertainty (FU), Intimate Relationships (IR), Social Health (SH), and Cognitive Functioning (CF)) using two approaches: anchor-based and score distribution-based. Each MCID was estimated for improvement/deterioration both globally and separately for patients with a baseline PRQoL-HCV score ≤ 50 (group1) and patients with a baseline PRQoL-HCV score > 50 (group2).

Results

The pooled MCIDs for improvement/deterioration globally, in group1, and in group2, respectively, were as follows: 8.8/− 7.6, 9.7/− 9.5, and 6.0/− 6.9 for PH; 7.1/− 4.6, 7.7/− 9.6, and 6.6/− 6.7 for EH; 6.7/− 6.7, 8.2/− 8.2, and 6.0/− 6.0 for FU; 7.0/− 7.0, 5.4/− 5.4, and 6.2/− 6.2 for IR; 7.7/− 7.7, 8.6/− 8.6, and 6.5/− 6.5 for SH; 7.3/− 5.6, 9.1/− 8.0, and 6.5/− 6.3 for CF.

Conclusions

The overall MCID for the PROQOL-HCV scores ranged from 6.7 to 8.8 for improvement and from − 7.7 to − 4.6 for deterioration. The effect of DAA on PROQOL-HCV scores seemed particularly beneficial for patients with lower baseline scores. This subgroup could be motivated to take DAA if they are informed of the benefits for their HRQoL.
Literatuur
1.
go back to reference Marcellin, F., Roux, P., Protopopescu, C., Duracinsky, M., Spire, B., & Carrieri, M. P. (2017). Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: Current knowledge and outstanding issues. Expert Review of Gastroenterology & Hepatology, 11(3), 259–268. https://doi.org/10.1080/17474124.2017.1285227CrossRef Marcellin, F., Roux, P., Protopopescu, C., Duracinsky, M., Spire, B., & Carrieri, M. P. (2017). Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: Current knowledge and outstanding issues. Expert Review of Gastroenterology & Hepatology, 11(3), 259–268. https://​doi.​org/​10.​1080/​17474124.​2017.​1285227CrossRef
9.
go back to reference Duracinsky, A. A. M., Herrmann, S., Lalanne, C., Galano, E., Da Silva, M. H., Carrieri, P. M., & Chassany, O. (2015). "PIN90 -psychometric validation of the new international questionnaire to assess health-related quality of Life (Hrql) specific to viral hepatitis C: Proqol-Hcv. Value in Health, 18(7), A591–A592. https://doi.org/10.1016/j.jval.2015.09.1523CrossRef Duracinsky, A. A. M., Herrmann, S., Lalanne, C., Galano, E., Da Silva, M. H., Carrieri, P. M., & Chassany, O. (2015). "PIN90 -psychometric validation of the new international questionnaire to assess health-related quality of Life (Hrql) specific to viral hepatitis C: Proqol-Hcv. Value in Health, 18(7), A591–A592. https://​doi.​org/​10.​1016/​j.​jval.​2015.​09.​1523CrossRef
21.
go back to reference D. W. Hosmer and S. Lemeshow, Applied logistic regression (Wiley series in probability and mathematical statistics). New York, NY; Chichester: Wiley, 1989. D. W. Hosmer and S. Lemeshow, Applied logistic regression (Wiley series in probability and mathematical statistics). New York, NY; Chichester: Wiley, 1989.
23.
go back to reference M. B. Patrizia Carrieri, Vincent Di Beo, Clovis Lusivika-Nzinga, Clémence Ramier, Saskia Antwerpes, Camelia Protopopescu, 2023 Jean-Marc Lacombe, Stanislas Pol, Hélène Fontaine, Abbas Mourad, Fabrice Carrat, Martin Duracinsky, Fabienne Marcellin. , "Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort)," Quality of Life Research (sous presse). M. B. Patrizia Carrieri, Vincent Di Beo, Clovis Lusivika-Nzinga, Clémence Ramier, Saskia Antwerpes, Camelia Protopopescu, 2023 Jean-Marc Lacombe, Stanislas Pol, Hélène Fontaine, Abbas Mourad, Fabrice Carrat, Martin Duracinsky, Fabienne Marcellin. , "Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort)," Quality of Life Research (sous presse).
Metagegevens
Titel
Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV)
Auteurs
Mourad Abbas
Carrieri Patrizia
Marcellin Fabienne
Bourliere Marc
Parlati Lucia
Carrat Fabrice
Duracinsky Martin
Protopopescu Camelia
Publicatiedatum
05-04-2024
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 6/2024
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-024-03622-2

Andere artikelen Uitgave 6/2024

Quality of Life Research 6/2024 Naar de uitgave